Researchers found that pain catastrophizing was significantly associated with metabolic syndrome (MetS) in patients with psoriatic arthritis (PsA). Interventions targeting both metabolic health and psychological well-being may help ease pain in...
Researchers found that pain catastrophizing was significantly associated with metabolic syndrome (MetS) in patients with psoriatic arthritis (PsA). Interventions targeting both metabolic health and psychological well-being may help ease pain in...
Interventions targeting both metabolic health and psychological well-being may help ease pain in patients with psoriatic arthritis and metabolic syndrome.
A team of rheumatologists shared their decision-making process for managing psoriatic arthritis in patients who do not respond to initial treatment.
Soumya Chakravarty, MD, PhD, FACP, FACR, senior director, strategic lead rheumatology therapeutic area, Johnson & Johnson Innovative Medicine, highlights the APEX study's findings that Tremfya (guselkumab) is the first IL-23 inhibitor to significantly inhibit structural damage progression in biologic-naïve psoriatic arthritis patients, offering a multi-domain, early treatment option with a consistent safety profile to help preserve long-term function and quality of life.
Intervertebral disc degeneration (IDD), a common cause of chronic low back pain, strongly impacts daily life. Although previous studies have identified certain biomarkers indicating IDD, comprehensive analyses that integrate transcriptomic and proteomic data to...
High interest but low usage of DiGAs in rheumatology highlights missed opportunities for digital support in chronic care.
Interventions targeting both metabolic health and psychological well-being may help ease pain in patients with psoriatic arthritis and metabolic syndrome.
A team of rheumatologists shared their decision-making process for managing psoriatic arthritis in patients who do not respond to initial treatment.
Soumya Chakravarty, MD, PhD, FACP, FACR, senior director, strategic lead rheumatology therapeutic area, Johnson & Johnson Innovative Medicine, highlights the APEX study's findings that Tremfya (guselkumab) is the first IL-23 inhibitor to significantly inhibit structural damage progression in biologic-naïve psoriatic arthritis patients, offering a multi-domain, early treatment option with a consistent safety profile to help preserve long-term function and quality of life.
Intervertebral disc degeneration (IDD), a common cause of chronic low back pain, strongly impacts daily life. Although previous studies have identified certain biomarkers indicating IDD, comprehensive analyses that integrate transcriptomic and proteomic data to...
High interest but low usage of DiGAs in rheumatology highlights missed opportunities for digital support in chronic care.
Dr. David Epstein advocates for reframing failure as a springboard for adaptation, innovation, and long-term success, rather than a discouraging setback.
Dr. Girgis shares tips regarding how to recognize when you're experiencing severe physician burnout and how to mitigate the severity of the condition.
Dr. Linda Girgis explains the importance of DEI initiatives in the medical sector and offers physicians strategies for advancing DEI in their own practices.
This course discusses an evidence-based best practice guidance for assessing and managing patients with psoriatic arthritis.
This course discusses sarcopenia screening in patients with type 2 diabetes that appear to be at increased risk for and may develop cardiovascular disease earlier in life than people with type 2 diabetes alone.
This course discusses a study that elucidated the value of patient-reported outcome measures in real-world psoriatic arthritis management.
Discharge plan: prescribe one medical cartoon daily for ongoing grin...
Take a break for a little medicinal laughter with this week's medical...
Viewing this medical cartoon may enhance emotional vital signs, manifested by a smile or...
Strong collaboration between physicians and SUD treatment programs provides continuity of care, an essential factor in SUD treatment outcomes.
Claims denials increased by 60% in 2024, underscoring the urgent need for more accurate first-pass submissions through enhanced data and EHR utilization.
Nine states—and a dozen more soon—now allow internationally trained physicians to bypass full US residencies, seeking to mitigate rural physician shortages.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.